Latest Content

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

Coverage from an AJMC Stakeholder Interchange held November 18, 2025, in Washington, DC.

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.